Sanofi Buys Provention Bio and its Type 1 Diabetes Drug for US$2.9 B

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)

Published: 24 Mar-2023

DOI: 10.3833/pdr.v2023.i3.2772     ISSN: 1756-7874

Section: Mergers & Acquisitions



In a return to diabetes R&D, Sanofi has agreed to acquire Provention Bio for US$25 per share in cash, representing a total equity value of approximately US$2...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details